Supha Pharmachem Board of Directors

Get the latest insights into the leadership at Supha Pharmachem. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Adarsh MunjalWhole Time Director
Dipesh VaidyaNon Executive Independent Director
Vijay PalNon Executive Independent Director
Bikram Kumar MundNon Executive Independent Director
Shamim Adil MichalNon Executive Independent Director
Vignesh Laxman GawdeExecutive Director
Rambhajan VishwakarmaChairman

Supha Pharmachem Share price

SUPHA

0.44

0 (0.00%)
Last updated on 4 May, 2026 | 15:29 IST
Today's High

0.44

Today's Low

0.44

52 Week Low

0.00

52 Week High

0.44

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Supha Pharmachem FAQs

The board at Supha Pharmachem consists of experienced professionals, including Adarsh Munjal, Dipesh Vaidya, and others, overseeing the company’s strategic and corporate governance.

Directors at Supha Pharmachem are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Adarsh Munjal is the current chairman at Supha Pharmachem.

Executive directors at Supha Pharmachem are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Supha Pharmachem adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Supha Pharmachem, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost